However, the follow-up duration in our series is short, limiting our ability to demonstrate that HR+/HER2- breast cancer patients with high KPNA2 but low FOXM1 mRNA levels exhibit significantly better survival outcomes beyond the TCGA cohorts. This evidence concerns the gene KPNA2 and breast cancer.